BibTex format

author = {Gu, B and Huang, Y and Manchester, E and Hughes, A and Thom, S and Chen, R and Xu, XY},
doi = {10.1007/s11095-021-03161-2},
journal = {Pharmaceutical Research},
pages = {41--56},
title = {Multiphysics modelling and simulation of thrombolysis via activated platelet-targeted nanomedicine},
url = {},
volume = {39},
year = {2022}

RIS format (EndNote, RefMan)

AB - Purpose:This study establishes a multiphysics simulation platform for both conventional and targeted thrombolysis using tissue plasminogen activator (tPA). Based on our computational results, the effects of therapeutic parameters on the dynamics of thrombolysis and the risk of side effects are investigated.Methods:The model extends our previously developed one-dimensional(1D) mathematical models for fibrinolysis by incorporating targeted thrombolysis. It consists of two parts: (i) a coupled mathematical model of systemic pharmacokinetics (PK) and pharmacodynamics (PD) and local PD in a 1D occluded artery, and (ii) a mechanistic model for a targeted thrombolytic system via activated platelet-targeted tPA-loaded nanovesicles (tPA-NV), with model parameters derived from our in vitro experiments. A total of 16 therapeutic scenarios are simulated by varying the clot location and composition as well as the dosing regimen with free tPA or tPA-NV.Results:Our simulation results indicate that tPA-NV offers several advantages over free tPA for thrombolysis. It reduces systemic exposure of tPA, thereby minimising the risk of bleeding complications. Simulations with different tPA-NV doses reveal that tPA-NV at 10% of the recommended dose can be as effective as the standard regimen with the full recommended dose of free tPA, demonstrating the potential of our tPA-NV as a new thrombolytic strategy with a reduced tPA dose. Moreover, faster recanalisation can be achieved with tPA-NV, especially for platelet-rich(or fibrin-poor) clots.Conclusions:Our simulation platform for thrombolysis with well-tuned model parameters can be used to evaluate and optimise treatment regimens of existing and new thrombolytic therapies via benefit/risk assessment under various therapeutic scenarios.
AU - Gu,B
AU - Huang,Y
AU - Manchester,E
AU - Hughes,A
AU - Thom,S
AU - Chen,R
AU - Xu,XY
DO - 10.1007/s11095-021-03161-2
EP - 56
PY - 2022///
SN - 0724-8741
SP - 41
TI - Multiphysics modelling and simulation of thrombolysis via activated platelet-targeted nanomedicine
T2 - Pharmaceutical Research
UR -
UR -
UR -
VL - 39
ER -